Cohen, Ezra E W;Soulières, Denis;Le Tourneau, Christophe;Dinis, José;Licitra, Lisa;Ahn, Myung-Ju;Soria, Ainara;Machiels, Jean-Pascal;Mach, Nicolas;Mehra, Ranee;Burtness, Barbara;Zhang, Pingye;Cheng, Jonathan;Swaby, Ramona F;Harrington, Kevin J;Acosta-Rivera, Mirelis;Adkins, Douglas R.;Aghmesheh, Morteza;Ahn, Myung-Ju;Airoldi, Mario;Aleknavicius, Eduardas;Al-Farhat, Yousuf;Algazi, Alain P.;Almokadem, Salah;Alyasova, Anna;Bauman, Jessica R.;Benasso, Marco;Berrocal, Alfonso;Bray, Victoria;Burtness, Barbara Ann;Caponigro, Francesco;Castro, Ana;Cescon, Terrence P.;Chan, Kelvin;Chaudhry, Arvind;Chauffert, Bruno;Cohen, Ezra;Csoszi, Tibor;De Boer, J.P.;Delord, Jean-Pierre;Dietz, Andreas;Dinis, Jose;Dupuis, Charlotte;Digue, Laurence;Erfan, Jozsef;Escobar Alvarez, Yolanda;Evans, Mererid;Fidler, Mary Jo;Forster, Martin David;Friesland, Signe;Ganti, Apar K.;Geoffrois, Lionnel;Grant, Cliona;Gruenwald, Viktor;Harrington, Kevin;Hoffmann, Thomas;Horvai, Geza;Inciura, Arturas;Jang, Raymond;Jankowska, Petra;Jimeno, Antonio;Joseph, Mano;Juarez Ramiro, Alejandro;Karaszewska, Boguslawa;Kawecki, Andrzej;Keilholz, Ulrich;Keller, Ulrich;Kim, Sung-Bae;Kocsis, Judit;Kotecki, Nuria;Kozloff, Mark F.;Lambea, Julio;Landherr, Laszlo;Lantsukhay, Yuri;Lazarev, Sergey Alexandrovich;Lee, Lip Way;Le Tourneau, Christophe;Licitra, Lisa;Lifirenko, Igor Dmitrievich;Mach, Nicolas;Martincic, Danko;Matorin, Oleg Vladmirovhich;McGrath, Margaret;Machiels, Jean-Pascal;Mehra, Ranee;Misiukiewicz, Krzysztof;Morris, John C.;Mufazalov, Fagim Fanisovich;Niu, Jiaxin;Pamoorthy Srinivasan, Devraj;Perez Segura, Pedro;Rauch, Daniel;Ribeiro, Maria Leonor;Rodriguez, Cristina;Rolland, Frederic;Russo, Antonio;Ruzsa, Agnes;Sanches, Frederico;Shin, Sang-Won;Shtiveland, Mikhail;Soulieres, Denis;Soria, Ainara;Specenier, Pol;Szekanecz, Eva;Szota, Judit;van Herpen, Carla M.L.;Velez-Cortes, Hector A.;Walsh, William V.;Wilop, Stefan;Winterhalder, Ralph;Wojtukiewicz, Marek;Wong, Deborah;Zandberg, Dan
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
The Lancet
2019
393
10167
156-167